Unique genomic alterations in the circulating tumor DNA of patients with solid tumors brain metastases.

When assessing OS from first BrM, there was a clear trend towards improvement when ctDNA MAF was < 1% versus ≥ 1%, suggesting clinical significance ( Figure 1 ).

also in 19,460 other papers